News/ News/ Oncology IO Biotech raises $155m to develop breakthrough cancer vaccine Richard Staines IO Biotech, melanoma, Novo Seeds, Oncology, R&D, vaccine 0 Comment IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) Share X IO Biotech raises $155m to develop breakthrough cancer vaccine https://pharmaphorum.com/news/io-biotech-raises-155m-to-develop-breakthrough-cancer-vaccine/
IO Biotech, melanoma, Novo Seeds, Oncology, R&D, vaccine
0 Comment
